NeuBase Therapeutics Inc
NASDAQ:NBSE
Earnings Announcements
Neubase Therapeutics Estimates Cash And Cash Equivalents Are Sufficient To Fund Currently Planned Operating & Capex Into Q1 Of Cy2022
Published: 12/23/2020 21:25 GMT
NeuBase Therapeutics Inc (NBSE) - Neubase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020.
Neubase Therapeutics - Estimates Cash and Cash Equivalents Are Sufficient to Fund Currently Planned Operating & Capex Into Q1 of Cy2022.
Neubase Therapeutics - Estimates Cash and Cash Equivalents Are Sufficient to Fund Currently Planned Operating & Capex Into Q1 of Cy2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.12
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.11
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.12
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.11
More details on our Analysts Page.